Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics Inc (SER) is a clinical-stage biotechnology innovator advancing neurological and pain therapies through its proprietary POZ Platform technology. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory developments, and strategic partnerships. Our curated collection includes press releases on drug candidate advancements, peer-reviewed research findings, and executive commentary – all essential for understanding SER's position in biopharmaceutical innovation.
Key focus areas include updates on the POZ Platform's application in drug delivery systems, trial phase transitions, and collaborative research initiatives. Content is organized to provide clear context about how each development aligns with the company's mission to improve neurological and pain management therapies.
Bookmark this page for direct access to primary source materials from Serina Therapeutics. Check regularly for new insights into the company's scientific advancements and operational milestones in the competitive biotech landscape.
Serina Therapeutics, a clinical-stage biotech company listed on NYSE American under ticker SER, has announced its participation in the upcoming JonesResearch Virtual CNS Day. The company, known for developing the proprietary POZ Platform™ drug optimization technology, will be represented by CEO Steve Ledger in a fireside chat presentation.
The virtual event is scheduled for April 29, 2025, at 12:00 p.m. EDT. Registered attendees can access the live webcast through a provided Zoom link. For those unable to attend the live session, an archived replay will remain available on-demand for 90 days after the event.
Serina Therapeutics (NYSE: SER) announced that their Chief Development Officer, Dr. Randall Moreadith, will present groundbreaking data at the 4th LNP Formulation & Process Development Summit 2025 in Boston. The presentation, titled 'The PEG Dilemma – A Solution,' will take place on April 15, 2025, at 9:30 AM ET.
The presentation focuses on the company's innovative POZ-lipid technology, developed as an immune-silent alternative to PEG-lipids in mRNA vaccines and therapeutics. Key research findings show that Serina's POZ-lipid component in lipid nanoparticles (LNPs) demonstrated no IgM or IgG antibody response in rat studies with repeat dosing, unlike traditional PEG-lipid standards which triggered strong antibody responses.
This breakthrough is particularly significant as anti-PEG antibodies have been linked to anaphylaxis and serious adverse events in patients receiving PEGylated mRNA vaccines, including those from Pfizer and Moderna. The immune-silent nature of POZ-lipid technology could potentially revolutionize the development of safer LNP formulations for gene therapy and RNA-based medicines.
Serina Therapeutics (NYSE: SER) has secured $5 million in strategic funding to advance its lead clinical candidate SER-252 for Advanced Parkinson's disease. The financing involves issuing 965,250 shares of convertible preferred stock at $5.18 per share.
The funds will support the development of SER-252 (POZ-apomorphine), which utilizes Serina's proprietary POZ Platform™ drug optimization technology. The company aims to initiate a Phase 1 clinical trial in the fourth quarter of 2025. The therapeutic approach focuses on achieving continuous dopaminergic stimulation for potential clinical benefits in advanced Parkinson's disease patients.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. The company's CEO Steve Ledger will deliver a presentation on April 9, 2025, at 3:00 p.m. PDT.
Serina, known for developing its proprietary POZ Platform™ drug optimization technology, will make the presentation available via live webcast for registered attendees. The presentation recording will remain accessible on-demand for a 90-day period following the event.
Serina Therapeutics (NYSE: SER) reported its full year 2024 financial results, marking significant developments in its POZ Platform™ drug optimization technology. The company secured a $10 million equity financing from JuvVentures and completed the sale of UniverXome subsidiary, eliminating $11.2 million in debt.
Financial highlights include:
- Revenue decreased to $56,000 in 2024 from $3.2 million in 2023
- Operating expenses increased to $17.1 million from $6.3 million
- Net loss of $11.1 million ($1.51 per share) compared to net income of $5.3 million in 2023
- Cash position of $3.7 million as of December 31, 2024
The company strengthened its board with two appointments and advanced its partnership with Enable Injections for SER-252 development in advanced Parkinson's disease, with Phase 1b trial expected in Q4.
Serina Therapeutics (NYSE: SER) announced that their Chief Development Officer, Dr. Randall Moreadith, will present groundbreaking data at the ACS Spring 2025 Meeting in San Diego. The presentation, focusing on their POZ Platform™ drug delivery technology, will showcase findings on their proprietary POZ-lipid technology used in lipid nanoparticles (LNPs).
Key research findings demonstrate that Serina's POZ-lipid showed no IgM or IgG antibody response in rats after repeated dosing, unlike conventional polyethylene glycol (PEG)-lipids which triggered strong antibody responses. This is particularly significant as anti-PEG antibodies have been linked to anaphylaxis and serious adverse events in patients receiving PEGylated mRNA vaccines.
This breakthrough discovery suggests potential for developing safer and more effective LNP formulations for gene therapy and RNA-based medicines.
Serina Therapeutics (NYSE American: SER) has appointed Dr. Jay Venkatesan to its Board of Directors. Dr. Venkatesan brings extensive experience in biotechnology investment and company building, most recently serving as Chairman, President, and CEO of Angion Biomedica until its 2023 merger with Elicio Therapeutics.
His notable achievements include co-founding Alpine Immune Sciences, which was acquired by Vertex Pharmaceuticals for $4.9 billion in May 2024. Dr. Venkatesan's background includes founding Ayer Capital, a healthcare investment fund, and holding positions at Brookside Capital and McKinsey & Co.
As part of this transition, Serina's co-founder Dr. Milton Harris will become Director Emeritus and Chair of the company's Scientific Advisory Board (SAB), continuing to provide guidance for the company's research and development efforts.
Serina Therapeutics (NYSE: SER) has successfully closed the second $5 million tranche of its $10 million equity financing with JuvVentures (UK) . This funding will support the advancement of SER-252, a treatment for advanced Parkinson's disease, into Phase 1 clinical trials in the second half of 2025.
The transaction involved issuing 500,000 shares at $10 per share, representing a 113% premium to the January 31, 2025 closing price. Additionally, warrants for up to 755,728 shares at $18.00 per share were issued to JuvVentures. The company's POZ Platform™ drug optimization technology enables SER-252 (POZ-apomorphine) to provide continuous dopaminergic stimulation through an innovative drug delivery system.
Serina Therapeutics (NYSE American: SER) has announced the sale of its UniverXome subsidiary, completed on December 23, 2024. The transaction eliminates $11.2 million in subsidiary-level debt, resulting in a debt-free balance sheet for Serina entering 2025.
The UniverXome subsidiary was established before Serina's reverse merger with AgeX Therapeutics in March 2024 to hold legacy assets. This strategic move aligns with Serina's focus on advancing SER-252, their lead candidate for advanced Parkinson's disease, into clinical development. The company aims to explore their POZ Platform™ technology across multiple therapeutic applications, including small molecules, lipid nanoparticles (LNPs), and antibody-drug conjugates (ADCs).
Serina Therapeutics (NYSE American: SER) has announced the appointment of Karen J. Wilson to its Board of Directors. Wilson brings over 30 years of leadership experience in life sciences, currently serving on the boards of Connect Biopharma Holdings, Elicio Therapeutics, and LAVA Therapeutics.
Wilson previously held senior finance positions at Jazz Pharmaceuticals, including Senior Vice President of Finance and Principal Accounting Officer. Her prior experience includes senior finance roles at PDL BioPharma, ViroLogic, and Novare Surgical Systems, as well as consulting and auditing at Deloitte & Touche LLP. She is a Certified Public Accountant with a B.S. in Business from UC Berkeley.
The company also announced the departure of Steven Mintz from its Board of Directors, who helped guide Serina's transition from private to public company.
FAQ
What is the current stock price of Serina Therapeutics (ser)?
What is the market cap of Serina Therapeutics (ser)?
